Zymeworks (ZYME) Misses Q4 EPS, Revenue Beats

Zymeworks (NASDAQ: ZYME) reported Q4 EPS of $4.71, $0.13 worse than the analyst estimate of $4.84. Revenue for the quarter came in at $402.49 million versus the consensus estimate of $371.3 million.

For earnings history and earnings-related data on Zymeworks (ZYME) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• UBS Starts CSE Global (CSE:SP) (CSYJF) at Buy
• JPMorgan Downgrades Chewy Inc. (CHWY) to Neutral